Grants and Contributions:
Title:
COVID-19 Response (VI): STAGE 2 Oral DNA Vaccine Development
Agreement Number:
974484
Agreement Value:
$3,071,774.00
Agreement Date:
Jun 1, 2021 - Mar 31, 2023
Description:
This project will involve further development and characterization of oral bacTRL-based vaccines. This work includes the preclinical development of additional bacTRL-based products including emergent or predicted SARS-CoV-2 variants, as well as the continued evaluation of the lead vaccine candidate in a Phase I clinical trial.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5J 5J8
Reference Number:
172-2021-2022-Q1-974484
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
818996241
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -1,500,000 dollars.
Amendment Date
Jan 28, 2023
Recipient's Operating Name:
Alexander Graves
Recipient's Legal Name:
Symvivo Corporation
Federal Riding Name:
Burnaby South
Federal Riding Number:
59003
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: